Windlas Biotech shareholders approved a final dividend of ₹6.30 per equity share for the financial year ended March 31, 2026, and reappointed key board members at its 25th Annual General Meeting (AGM) held on July 23, 2026. The meeting, conducted through Video Conferencing (VC) / Other Audio-Visual Means (OAVM), saw strong shareholder engagement with 14,732,527 votes polled out of 20,636,229 shares held by eligible members, resulting in a 71.39% voting participation rate. All ordinary and special resolutions were passed with requisite majority, reflecting unified support for the company’s financial and governance decisions.

The AGM agenda included the adoption of audited standalone and consolidated financial statements for FY26, alongside the declaration of the final dividend. Shareholders also ratified the remuneration of the Cost Auditor. The voting process was scrutinized by Mr. Sandeep Joshi of M/s Sandeep Joshi & Associates, Practicing Company Secretary (Membership No. ACS-42945), who submitted his consolidated report on July 24, 2026, under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice for the AGM was dispatched on July 1, 2026, to 45,596 registered members, with remote e-voting open from July 20 to July 22, 2026.

Board Reappointments and New Appointment

Shareholders reappointed Hitesh Windlass, Managing Director (DIN: 02030941), and Prachi Jain Windlass, Director (DIN: 06661073), both of whom were liable to retire by rotation but offered themselves for re-appointment. Both resolutions received 100% support from the votes polled. Additionally, the company passed a special resolution to appoint Dr. Tarashree Singhal (DIN: 11697518) as an Independent Director, which also secured unanimous approval. These appointments ensure continuity in leadership while strengthening the independent oversight on the Board.

Voting Participation Analysis

The high voting turnout underscores active shareholder involvement in corporate governance matters. Promoter and Promoter Group entities held 13,065,352 shares and voted 13,065,349 shares, representing 100% participation within their category. Public institutional investors held 2,412,429 shares and cast 1,522,146 votes, yielding a 63.10% participation rate. Public non-institutional shareholders held 5,158,448 shares and cast 145,032 votes, corresponding to a 2.81% participation rate. The disparity in participation rates between promoter/institutional holders and retail non-institutional holders is typical in Indian listed companies, where large block holders engage more consistently in e-voting processes. The cut-off date for determining voting entitlement was July 16, 2026.

Windlas Biotech has scheduled a virtual meeting for analysts and institutional investors on July 14, 2026. The session is set to commence at 3:00 PM IST and will be conducted in a group format. This initiative is part of the company's engagement efforts under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company confirmed that the discussions during the meeting will be based solely on publicly available documents. It explicitly stated that no unpublished price sensitive information (UPSI) will be shared during the session. Windlas Biotech noted that the schedule is subject to change due to exigencies on the part of investors, analysts, or the company.

Meeting Details

The intimation was submitted to the stock exchanges pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Ananta Narayan Panda, Company Secretary & Compliance Officer, signed the filing on July 9, 2026.